投资咨询业务资格:证监许可【2012】31号 == 宏观金融数据日报 ITG 国贸期货 世界500强投资企业 国贸期货有限公司 成为一流的衍生品综合服务商 B E W S B B B A 热 线 官 方 网 站 81 用版 400-8888-598 www.itf.com.cn ITCE 离期货 | | 国贸期货研究院 期货执业证号:F3074875; 2025/7/11 宏观金融研究中心 郑雨婷 投资咨询证号: Z0017779 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | 较前值变动 (bp) | | 4-6 | DR001 | 1.32 | 0.58 | DR007 | 1.49 | 1.78 | | E | GC001 | 1.16 | -27.50 | GC007 | 1.49 | -2.00 | | | SHBOR 3M | 1.56 | -0.30 | LPR 5年 | 3.50 | 0.00 | | D | 1年期国债 | 1.37 | 1.25 | 5 ...

周五，热景生物股价20CM涨停，股价创下历史新高，最新总市值为180.6亿元。 自去年9月18日以来，热景生物股价累计涨超724.8%，最低触及22.94元/股，最高达194.81元/股。 | → 分时 ■ 周 月 季 年 1分 5分 15分 30分 60分 30s ▼ 多周期 设置 | | | | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | | | | | | 日线(复权) 热景生物 MA5: 160.15↑ MA10: 149.86↑ MA20: 148.87↑ MA30: 141.63↑ MA60: 129.14↑ | | | | | | | | 《 个股K线区间统计 | | | X | | | | | | | | | 起始时间: 2024-09-18 | | | 周期个数: | | | | | | | | | 终止时间: 2025-07-04 | | | 191个 | | | | | | | | | 起始价: | 23.62 | 终止价: | 194.81 | | | | | | | ...

投资咨询业务资格:证监证可【2012】31号 股 損 行 情 综 试 宏观金融数据日报 | | 国贸期货研究院 宏观金融研究中心 郑雨婷 | | 期货执业证号:F3074875; 投资咨询证号: Z0017779 | | 2025/7/4 | | | --- | --- | --- | --- | --- | --- | --- | | | 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | 较前值变动 (bp) | | | DR001 | 1.51 | -4.43 | DR007 | 1.91 | -3.79 | | | GC001 | 1.15 | -20.00 | GC007 | 1.49 | -1.50 | | ह | | | | | | | | | SHBOR 3M | 1.61 | -1.35 | LPR 5年 | 3.50 | 0.00 | | 而 | 1年期国债 | 1.34 | -0.50 | 5年期国债 | 1.49 | 0.50 | | 市 | | | | | | | | | 10年期国债 | 1.65 | 0.10 | 10年期美债 | 4.30 | 4.00 | | ...

宏观金融数据日报 | | 国贸期货研究院 期货执业证号:F3074875; 2025/7/3 | | | | | | | --- | --- | --- | --- | --- | --- | --- | | | 宏观金融研究中心 郑雨婷 投资咨询证号: Z0017779 | | | | | | | | 较前值变动 品种 | 收盘价 | 较前值变动(bp) | 品种 | 收盘价 | | | | | | | | | (bp) | | स्टे | DR001 | 1.51 | 14.09 | DR007 | 1.91 | 20.92 | | E | GC001 | 1.35 | -11.00 | GC007 | 1.50 | -8.00 | | F | SHBOR 3M | 1.62 | -0.85 | LPR 5年 | 3.50 | 0.00 | | 场 | 1年期国债 | 1.34 | -0.50 | 5年期国债 | 1.49 | 0.50 | | 与 | 10年期国债 | 1.65 | 0.10 | 10年期美债 | 4.26 | 2.00 | | 流 | 回顾:央行昨日开展了3315亿元7天期逆回购操作 ...

证券分析师 张浩 资格编号：S0120524070001 邮箱：zhanghao3＠tebon.com.cn 研究助理 [Table_Main] 证券研究报告 | 宏观专题 2025 年 07 月 02 日 宏观专题 相关研究 德邦证券 7 月研判及金股 [Table_Summary] 投资要点： 宏观研判：攻守兼备、以逸待劳 德邦证券 2025 年 7 月金股组合 化工 卓越新能（688196.SH）：中国生物柴油工业化生产先驱；生物柴油紧平衡格局 延续，关注原料替代与贸易突围；反倾销危局催动全球布局，渠道自主重构破贸易壁 请务必阅读正文之后的信息披露和法律声明 副标题：楷体四号，非必填 当前影响整个市场的宏观变量主要是三个方面——内需修复进程、政策落地效果 和外部环境变化，眼下宏观领域的一系列分歧本质上是对这三方面宏观变量存在 不同的假设和推演，我们认为资产配置要攻守兼备、以逸待劳，在不确定性中寻找 确定性，把握趋势并做好应对。 一、外部环境方面，中美关税谈判的缓和有助于缓释基本面及市场风险偏好的压 力，中长期中美关系依旧处于一个竞争高于合作的阶段，特朗普政府依旧将"去风 险化"作为重要战略方向，这意味着 ...

证券研究报告 | 宏观专题 2025年07月02日 德邦证券7月研判及金股 宏观专题 投资要点: 资格编号: S0120524070001 预期. 后者则是立足绝对收益思维,建议关注铜、铝、稀土、锡等;债券:预计利 率债低位震荡概率较高。信用利差已处于历史级"低位",建议关注类债资产与转 债机会。 · 德邦证券 2025年7月金股组合 化工 卓越新能(688196.SH):中国生物柴油工业化生产先驱;生物柴油紧平衡格局 延续,关注原料替代与贸易突围;反倾销危局催动全球布局,渠道自主重构破贸易壁 请务必阔读正文之后的信息披露和法律声明 证券分析师 张浩 邮箱:zhanghao3@tebon.com.cn 研究助理 相关研究 · 宏观研判:攻守兼备、以逸待劳 ● 当前影响整个市场的宏观变量主要是三个方面 -- 内需修复进程、政策落地效果 和外部环境变化,眼下宏观领域的一系列分歧本质上是对这三方面宏观变量存在 不同的假设和推演,我们认为资产配置要攻守兼备、以逸待劳,在不确定性中寻找 确定性,把握趋势并做好应对。 ● 一、外部环境方面,中美关税谈判的缓和有助于缓释基本面及市场风险偏好的压 力,中长期中美关系依旧处于一 ...

Core Viewpoint - The overnight repo rates at the exchange have increased, with GC001 reported at 3.45% and R001 at 3.31% at midday closing [1] Group 1 - The GC001 rate, which reflects the general collateral overnight repo rate, is currently at 3.45% [1] - The R001 rate, indicating the reverse repo rate, stands at 3.31% [1]

Core Viewpoint - The Daxing Biomedical Industry Base, known as "China Pharmaceutical Valley," is accelerating its development in the life and health industry, aiming for high-quality growth and international influence by 2025 [1][3][13]. Group 1: Industry Development - The life and health industry is a strategic emerging industry crucial for national security and public welfare, with Daxing District being a key area for its development in Beijing [3][4]. - The Daxing Biomedical Industry Base has expanded by 9.1 square kilometers, enhancing its capacity for industrial research and production, as well as supporting services [4]. - The base is set to strengthen its core industries, including vaccines, traditional Chinese medicine, and high-end medical devices, while also exploring new sectors like medical aesthetics and animal pharmaceuticals [7][13]. Group 2: Project Initiatives - Several high-impact biomedical projects are set to be established in the Daxing Biomedical Industry Base, including innovative drug development and antibody production [6]. - The second phase of the China Food and Drug Inspection Institute's project has commenced, significantly boosting the region's research and testing capabilities [5]. - The base is actively promoting the construction of a new campus for Capital Medical University, which will enhance research innovation and industry integration [4]. Group 3: Technological Integration - The Daxing Biomedical Industry Base is leveraging big data and artificial intelligence to enhance its service and digital capabilities across various sectors [8][10]. - The base is transitioning from a product-oriented approach to a service-oriented model, exemplified by the establishment of a new retail consumption model by Tongrentang Health [8]. - Advanced AI technologies are being integrated into drug research and development, marking a significant shift towards innovative pharmaceutical solutions [10]. Group 4: Policy and Support - The Daxing Biomedical Industry Base is implementing a "one-stop service platform" to optimize the business environment and support enterprises in accessing various policy benefits [12]. - The base has facilitated the application of over 50 projects for national and municipal policy support, enhancing the operational capabilities of more than 30 enterprises [12]. - The base is committed to fostering a collaborative ecosystem by establishing shared platforms for high-value instruments and equipment among research institutions [11].

Core Viewpoint - The second largest shareholder of Hotgen Biotech, Zhou Xin, plans to reduce his stake in the company after a significant increase in stock price, indicating potential liquidity needs and market volatility [2][5]. Shareholder Actions - Zhou Xin intends to sell up to 1.8 million shares, representing approximately 1.94% of the total share capital, to meet personal funding requirements [2]. - As of the announcement date, Zhou Xin holds 6.8066 million shares, accounting for 7.342% of the total shares [3]. Financial Performance - In 2024, Hotgen Biotech reported a revenue of 511 million yuan, a year-on-year decrease of 6.74%, and a net loss of 191 million yuan, a significant decline of 760.4% [7]. - The company experienced a surge in performance during the COVID-19 pandemic in 2021, but both revenue and stock price have since declined sharply [6]. Historical Cashing Out - Prior to the current planned reduction, Zhou Xin has already cashed out approximately 2.1 billion yuan from his holdings in Hotgen Biotech since its IPO [4]. - His previous cashing out included approximately 21.59 million yuan in 2017 and 65.59 million yuan in 2018, totaling around 87.17 million yuan over those two years [4]. Market Context - Hotgen Biotech's stock price has seen a dramatic increase of over 6 times since late September 2024, similar to a previous surge of 5 times in April 2021 [5]. - As of June 25, 2024, the stock closed at 137.2 yuan per share, giving the company a market capitalization of 12.7 billion yuan [11]. Strategic Developments - The company is focusing on innovative biopharmaceutical technologies through its "Future Technology Research Institute," with strategic investments in companies developing cutting-edge antibody and nucleic acid drugs [11].

【导读】热景生物第二大股东拟减持不超过180万股公司股份 中国基金报记者 卢鸰 在股价暴涨超6倍后，热景生物第二大股东周锌又要减持。此前，在周锌于2021年7月减持前，热景生物股价在 当年 4月曾 一 月暴涨5 倍。 据热景生物6月25日晚公告，公司近日收到股东周锌发出的《关于减持公司股份的告知函》。因自身资金需求，股东周锌计划通过集中竞 价、大宗交易方式减持所持公司股份合计不超过180万股，占公司总股本的1.9416%。 以热景生物6月25日的收盘价估算，此次减持周锌将最 多 套现约2.5亿元。 总计 已 套现约2.1亿元 2019年9月热景生物在科创板上市时，周锌所持股份占比为10.35%，是公司第二大股东。 截至公告披露日，周锌仍为热景生物第二大股东，持有公司股份680.66万股，占公司股份总数的7.342% 。其 股份来源于公司首次公开发 行前持有及资本公积转增股本取得，已上市流通。 据招股书披露，通过协议转让方式，在上市前的2017年，周锌曾套现约2158.89万元，2018年又套现约6558.82万元，两年总计套现约 8717.71万元。 根据Wind数据，上市之后，通过二级市场，周锌已减持套现约 ...